TSH Biopharm Corporation Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 112.16 million compared to TWD 98.85 million a year ago. Revenue was TWD 112.16 million compared to TWD 98.85 million a year ago. Net income was TWD 18.22 million compared to TWD 9.89 million a year ago. Basic earnings per share from continuing operations was TWD 0.47 compared to TWD 0.26 a year ago. Diluted earnings per share from continuing operations was TWD 0.47 compared to TWD 0.26 a year ago.
For the nine months, sales was TWD 342.23 million compared to TWD 305.89 million a year ago. Revenue was TWD 342.23 million compared to TWD 305.89 million a year ago. Net income was TWD 53.92 million compared to TWD 32.62 million a year ago. Basic earnings per share from continuing operations was TWD 1.4 compared to TWD 0.85 a year ago. Diluted earnings per share from continuing operations was TWD 1.4 compared to TWD 0.85 a year ago.